Mutation status of epidermal growth factor receptor and clinical features of patients with combined small cell lung cancer who received surgical treatment

Lu,Hong-Yang; Mao,Wei-Min; Cheng,Qiao-Yuan; Chen,Bo; Cai,Ju-Fen; Wang,Xiao-Jia; Wang,Zeng; Xie,Fa-Jun

doi:10.3892/ol.2012.666

Mutation status of epidermal growth factor receptor and clinical features of patients with combined small cell lung cancer who received surgical treatment

Authors:
- Hong-Yang Lu
- Wei-Min Mao
- Qiao-Yuan Cheng
- Bo Chen
- Ju-Fen Cai
- Xiao-Jia Wang
- Zeng Wang
- Fa-Jun Xie
View Affiliations

Affiliations: Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology (esophagus, lung), Zhejiang Province, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022, P.R. China, Department of Traditional Chinese Medicine, Zhejiang Institute for Food and Drug Control, Hangzhou, Zhejiang 310004, P.R. China, Department of Pathology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022, P.R. China, Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022, P.R. China, Department of Pharmacology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022, P.R. China
Published online on: April 2, 2012 https://doi.org/10.3892/ol.2012.666
Pages: 1288-1292

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The mutation status of epidermal growth factor receptor (EGFR) is correlated with the response of tumors to EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC), suggesting its usefulness as a biomarker in NSCLC. The incidence of EGFR mutation in NSCLC is higher in China than in the United States and European countries. There have been some case reports concerning cases of gefitinib-responsive small cell lung cancer (SCLC) with EGFR mutations. However, few large studies concerning the mutation status of SCLC patients have been performed. We detected EGFR mutations in exons 19 and 21 of 40 SCLC patients, three of whom had combined SCLC, from the Zhejiang Cancer Hospital using xTAG technology. Only two patients with combined SCLC had an EGFR mutation in exon 19. To determine the EGFR mutation status and clinical features of combined SCLC, we retrospectively analyzed the clinical features of seven patients with combined SCLC who had undergone surgical treatment in Zhejiang Cancer Hospital between 2007 and 2010. EGFR mutations in exons 19 and 21 were detected using the pyrosequencing assay. Of the seven patients with combined SCLCs, 71.4% were male, 71.4% were heavy smokers, most were over 60 years old and 71.4% of the cases were combined adenocarcinoma. Chemotherapy treatment and tumor stage were correlated with survival time. Of the seven cases, one had a mutation in exon 19 of EGFR in both the conventional SCLC and SCLC combined adenocarcinoma components. Combined SCLC commonly occurs in patients who are heavy smokers, male and over 60 years old, and most of the combined type cases are adenocarcinoma. The treatment of combined SCLC may be applied to cases of conventional SCLC. EGFR mutations may therefore occur in combined SCLCs, especially in SCLC combined adenocarcinoma in China.

View Figures

View References

1	Mok TS, Wu YL, Thongprasert S, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
2	Maemondo M, Inoue A, Kobayashi K, et al: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
3	Mitsudomi T, Morita S, Yatabe Y, et al: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 11:121–128. 2010. View Article : Google Scholar
4	Rosell R, Gervais R, Vergnenegre A, et al: Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial. J Clin Oncol. 29(Suppl): abs.75032011.
5	Zhou C, Wu YL, Chen G, et al: Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 12:735–742. 2011. View Article : Google Scholar : PubMed/NCBI
6	Douillard JY, Shepherd FA, Hirsh V, et al: Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol. 28:744–752. 2010. View Article : Google Scholar : PubMed/NCBI
7	Okamoto I, Araki J, Suto R, et al: EGFR mutation in gefitinib responsive small-cell lung cancer. Ann Oncol. 17:1028–1029. 2006. View Article : Google Scholar : PubMed/NCBI
8	Zakowski MF, Ladanyi M, Kris MG, et al: EGFR mutations in small-cell lung cancers in patients who have never smoked. N Engl J Med. 355:213–215. 2006. View Article : Google Scholar : PubMed/NCBI
9	Qian J, Qin S, Tang Q, et al: Gefitinib in patients with advanced refractory small cell lung cancer contemporaneous with superior venacava syndrome. Chin Clin Oncol. 10:243–244. 2005.
10	Lu HY, Sun WY, Chen B, et al: Epidermal growth factor receptor mutations in small cell lung cancer patients who received surgical resection in China. Neoplasma. 59:100–104. 2012. View Article : Google Scholar : PubMed/NCBI
11	Govindan R, Page N, Morgensztern D, et al: Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 24:4539–4544. 2006.PubMed/NCBI
12	Mangum MD, Greco FA, Hainsworth JD, et al: Combined small-cell and non-small-cell lung cancer. J Clin Oncol. 7:607–612. 1989.PubMed/NCBI
13	Fraire AE, Johnson EH, Yesner R, et al: Prognostic significance of histopathologic subtype and stage in small cell lung cancer. Hum Pathol. 23:520–528. 1992. View Article : Google Scholar : PubMed/NCBI
14	Nicholson SA, Beasley MB, Brambilla E, et al: Small cell lung carcinoma (SCLC): a clinicopathologic study of 100 cases with surgical specimens. Am J Surg Pathol. 26:1184–1197. 2002. View Article : Google Scholar : PubMed/NCBI
15	Tatematsu A, Shimizu J, Murakami Y, et al: Epidermal growth factor receptor mutations in small cell lung cancer. Clin Cancer Res. 14:6093–6096. 2008. View Article : Google Scholar
16	Shiao TH, Chang YL, Yu CJ, et al: Epidermal growth factor receptor mutations in small cell lung cancer: a brief report. J Thorac Oncol. 5:195–198. 2011. View Article : Google Scholar : PubMed/NCBI
17	Shigematsu H, Lin L, Takahashi T, et al: Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 97:339–346. 2005. View Article : Google Scholar : PubMed/NCBI
18	Wu YL, Zhong WZ, Li LY, et al: Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China. J Thorac Oncol. 2:430–439. 2007. View Article : Google Scholar
19	Fukui T, Tsuta K, Furuta K, et al: Epidermal growth factor receptor mutation status and clinicopathological features of combined small cell carcinoma with adenocarcinoma of the lung. Cancer Sci. 98:1714–1719. 2007. View Article : Google Scholar : PubMed/NCBI
20	Dahabreh IJ, Linardou H, Siannis F, et al: Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res. 16:291–303. 2010. View Article : Google Scholar : PubMed/NCBI
21	Rostad H, Naalsund A, Jacobsen R, et al: Small cell lung cancer in Norway. Should more patients have offered surgical therapy? Eur J Cardiothorac Surg. 26:782–786. 2004. View Article : Google Scholar : PubMed/NCBI